Schizophrenia and Predominant Negative Symptoms

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Magnus Medical
Magnus MedicalCA - Burlingame
1 program
Neuronavigated Intermittent Theta Burst StimulationN/A1 trial
Active Trials
NCT07428460RecruitingEst. May 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
Magnus MedicalNeuronavigated Intermittent Theta Burst Stimulation

Clinical Trials (1)

NCT07428460Magnus MedicalNeuronavigated Intermittent Theta Burst Stimulation

Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia

Start: Feb 2026Est. completion: May 2028
N/ARecruiting

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)